We are on a mission to
Advance neonatal intensive care
The device is not yet authorized for marketing in the U.S or European Union
New standard in neonatal lung monitoring
Neola Medical develops Neola® — Neonatal Lung Analyzer — a class II medical device designed to advance neonatal intensive care. Our mission is to give preterm born babies a safer and stronger start in life by empowering healthcare professionals with non-invasive, continuous lung monitoring that enables instant detection of complications and provides critical insights needed to make life-saving decisions. The goal is earlier intervention, improved outcomes, and a new standard of care for the most fragile patients.
Neola® has the potential to upgrade the care of preterm born babies
- Unmet Clinical Need – 15 million babies are born preterm each year, with lung complications as a leading cause of mortality and long-term disability.
- Innovative Technology – Patented GASMAS method developed at Lund University, adapted for safe, non-invasive lung monitoring.
- Strong Market Potential – Pediatric devices represent an underdeveloped and fast-growing MedTech segment with recurring revenue opportunities from disposable probe sets.
- Scalable Business Model – Combination of one-time device sales and recurring revenue from single-use disposables ensures strong scalability and predictable revenue streams.
- Proven Team & Network – Experienced leadership with expertise in MedTech commercialization, supported by collaborations with leading NICUs in Sweden and the U.S.
NEOLA®
Neonatal Lung Analyzer
Recognition from leading experts in neonatology
Neola® has been recognised by leading experts in neonatology at Stanford University as a promising innovation with the potential to upgrade neonatal intensive care from the first day in the clinic. As a result, Neola Medical is one of the few companies that have been selected as a Stanford Impact1 company to receive support from the Stanford Impact1 program.
“I truly appreciate this as a neonatologist, as I frequently encounter cases of pneumothorax where a lung can collapse, and we do not detect it until vital signs begin to change.”
– Dr. Janene H. Fuerch, MD, Co-Director of Impact1, Clinical Associate Professor of Pediatrics, Division of Neonatal and Developmental Medicine at Stanford University School of Medicine, Medical Director, Neonatal ECMO at Stanford Children’s Hospital, Palo Alto, USA
CEO Hanna Sjöström and Dr. Janene H. Fuerch at the Stanford Impact1 CEO Summit 2023, first summit of the Stanford Impact1 program
Investor Presentations
Catch up on Neola Medical’s latest highlights, where CEO Hanna Sjöström shares insights into key milestones and the road ahead.
Explore Neola® – Neonatal Lung Analyzer
Hanna Sjöström, CEO of Neola Medical presents our innovative medical device Neola®
Company Milestones
2005
2016
Neola Medical AB is founded and headquartered in Lund, Sweden. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.
Lung Monitoring with Neola®
Preterm born babies face serious respiratory risks. Early detection can enable better outcomes and save lives.
How Neola® works
Our technology is designed to use safe infrared light to monitor the lungs continuously and non-invasively.
Research & Studies
Our clinical research is rooted in patented GASMAS technology developed at Lund University.
Stay updated on our progress and milestones
Neola Medical is currently in clinical phase with Neola®, undergoing our first clinical study on preterm born babies in Sweden. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.
Expert insights on our technology
Neola Medical was honored to sponsor a highly anticipated keynote lecture by esteemed U.S. Professor Vineet Bhandari, Division Head of Neonatology at The Children’s Regional Hospital at Cooper, Camden, USA. The keynote lecture was held at the Xth RECENT ADVANCES IN NEONATAL MEDICINE Congress, from October 12-14, 2024, in Würzburg, Germany.
Our story: Advanced technology with a Swedish heritage
Founded in 2016 in Lund, Sweden, with a U.S. office in Palo Alto, Neola Medical builds on Sweden’s historic legacy of medical technology innovation and contributions to global health care.
Sustainability and global health impact
By reducing reliance on invasive procedures, Neola® has the potential to improve patient safety and contribute to the UN Global Agenda 2030 goal of reducing neonatal mortality caused by preventable conditions.
Latest press releases
IECEE CB certificate by FORCE Technology
Neola Medical’s medical device for continuous monitoring of the lungs of preterm born infants, Neola®, has obtained a CB certificate, signifying that the product has undergone a rigorous and comprehensive testing and evaluation process at an accredited and independent IECEE testing house, FORCE Technology. The CB certificate is internationally recognized in about 50 countries and will form the basis for meeting the regulatory market requirements.
Certified according to ISO 13485
Neola Medical has undergone an extensive review process of its quality management system with an approved result, which means that the company is certified according to ISO 13485. The certification shows that the company has a well-reviewed and comprehensive quality management system for the development, sale, and fulfillment of regulatory market requirements of medical technology equipment.
Invest in Neola Medical
At Neola Medical, our mission is to provide preterm born babies with a stronger and safer start in life. Through our innovative medical device, Neola®, we aim to advance neonatal intensive care by offering non-invasive, continuous, real-time lung monitoring, with the potential to support proactive care, reduce morbidity and improve quality of life for these vulnerable patients.
"We aim to detect lung complications immediately, giving healthcare professionals the tools they need to make life-saving decisions."
– Hanna Sjöström, CEO Neola Medical